ClinicalTrials.gg
WithdrawnNCT01435902Updated Jun 23, 2014

A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

A Phase 3 interventional study of Fluticasone Furoate/Vilanterol Inhalation Powder and Fluticasone Propionate Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Withdrawn. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-06-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study was cancelled prior to enrolling any subjects

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
229th of 238
0 · median 93
Started
2012
with 22 others
Phase 3
61 of 262
6 open now
Registered
130th of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 229th largest by enrollment of the 238 interventional ones that give a count, is one of 23 that started in 2012, is one of 61 in phase 3, and was the 130th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate that the combination of inhaled fluticasone furoate/vilanterol (100 mcg/25 mcg) once daily provides superior protection throughout the day against bronchoconstriction induced by exercise compared with fluticasone propionate 250 mcg twice daily in adolescent and adult subjects aged 12 to 50 diagnosed with persistent asthma.

03

Conditions studied

  • Asthma

Keywords

  • exercise-induced bronchospasm
  • Activity/Exercise induced bronchospasm
  • asthma
04

Who can participate

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient male or female 12 to 50 years of age
  • Females of must be willing to use or commit to abstinence during the study
  • Diagnosis of persistent asthma for at least 6 months
  • Best pre-bronchodilator of at least 70%.
  • Current use of a low- to moderate-dose inhaled
  • Ability to withhold albuterol 6 hours prior to visits.
  • Physically able to perform exercise testing on a treadmill when albuterol has been withheld

Exclusion criteria

Exclusion Criteria:

  • Intermittent asthma, seasonal asthma, or exercise-induced asthma only
  • Symptomatic allergic rhinitis and/or thrush
  • Abnormal, electrocardigraph
  • Respiratory infection within 4 weeks of first visit leading to asthma medication change or could affect subjects's asthma status or participation
  • Asthma exacerbation within 12 weeks of first visit
  • Respiratory diseases or other concurrent disease that would put subject at risk or confound results interpretation
  • medicines within 30 days of first visit or less than five half-lives of medication in prior study
  • Allergy to study drugs or study drug
  • Concomitant medications that could interact with study medications or affect the course of asthma
  • Tobacco use within last year and/or a 10 pack-years history
  • Inability to comply with requirements of the study
  • Affiliation with investigator's site (example: family member)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Fluticasone Furoate/Vilanterol

    Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks

    Drug: Fluticasone Furoate/Vilanterol Inhalation Powder

  • Active comparator
    Fluticasone Propionate

    Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks

    Drug: Fluticasone Propionate Inhalation Powder

Interventions

  • DrugFluticasone Furoate/Vilanterol Inhalation Powder

    Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks

  • DrugFluticasone Propionate Inhalation Powder

    Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Maximal percent decrease from baseline in FEV1 following exercise challenge at 12 hours post-dose

    Time frame: At the end of treatment Week 4

Secondary outcomes

  1. Maximal percent decrease from baseline in FEV1 following exercise challenge at 1 hour and 23 hours post-dose

    Time frame: At the end of treatment Week 4

  2. Time required for recovery to within 5% of the pre-exercise baseline FEV1 from the time of the maximal percentage decrease from baseline following the challenge at 1 hour, 12 hours, and 23 hours post-dose

    Time frame: At the end of treatment Week 4

  3. AUC (0-60 minutes) for percentage decrease from baseline in FEV1 after exercise at 1 hour, 12 hours, and 23 hours post-dose

    Time frame: At the end of treatment Week 4

  4. Evaluation of a categorical treatment response using the percentage of subjects who demonstrate a decrease from the pre-exercise baseline in FEV1 of 1) <10%, 2) 10 to <20%, and 3) =/>20%.

    Time frame: At the end of treatment Week 4

  5. Maximal percent decrease from pre-randomized treatment baseline in FEV1 following exercise challenge at 1 hour, 12 hours, and 23 hours post-dose.

    Time frame: At the end of treatment Week 4

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 19, 2011
Start
Jan 2012
Primary completionEst.
Aug 2012
CompletionEst.
Aug 2012
Last update
Jun 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01435902
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Jan 2012
Primary completion
Aug 2012 (estimated)
Completion
Aug 2012 (estimated)
Last update
Jun 23, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion